Imagine a cancer patient embarking on chemotherapy. This path, while daunting, shines a beacon of hope for recovery. Yet unexpectedly, severe side effects derail their progress. Perplexed, the healthcare team scrambles for answers.
Chemotherapy drugs, especially those with fluoropyrimidine, are pivotal in cancer treatment. Nevertheless, individual responses to these drugs are unpredictably varied. Our genetic makeup dictates this variability.
Our DNA encodes instructions for medication metabolism, including chemotherapy drugs. The DPYD gene, in particular, is key for processing fluoropyrimidine-based treatments. Variations in this gene lead to different drug breakdown rates, resulting in varied treatment outcomes.
DPYD variant testing offers a solution. It involves analyzing a patient's genetic profile to identify DPYD mutations. Consequently, healthcare providers can tailor a treatment plan. This approach aims to enhance drug effectiv...
_____
If you are a member of our Association, please log in below to continue reading our exclusive content.
Not a member yet? Discover the benefits of joining our network and gain access to exclusive content like this for only $29.95 per month. Learn More and Sign Up
